TP53 modulates radiotherapy fraction size sensitivity in normal and malignant cells.

ABSTRACT: Recent clinical trials in breast and prostate cancer have established that fewer, larger daily doses (fractions) of radiotherapy are safe and effective, but these do not represent personalised dosing on a patient-by-patient basis. Understanding cell and molecular mechanisms determining fraction size sensitivity is essential to fully exploit this therapeutic variable for patient benefit. The hypothesis under test in this study is that fraction size sensitivity is dependent on the presence of wild-type (WT) p53 and intact non-homologous end-joining (NHEJ). Using single or split-doses of radiation in a range of normal and malignant cells, split-dose recovery was determined using colony-survival assays. Both normal and tumour cells with WT p53 demonstrated significant split-dose recovery, wher

SUBMITTER: Anbalagan S 

PROVIDER: S-EPMC8007815 | biostudies-literature | 2021 Mar

REPOSITORIES: biostudies-literature